AstraZeneca's Tezspire Meets Phase 3 Endpoints in Eosinophilic Esophagitis Trial

AstraZeneca (AZN) said Tuesday that full Phase 3 CROSSING trial results showed Tezspire improved disease remission and swallowing symptoms in patients with eosinophilic esophagitis, with benefits sustained through 52 weeks. At week 24, histologic remission was achieved by 64.8% of patients on 210 mg and 68.9% on 420 mg, versus 3.5% on placebo. Swallowing symptom scores improved by 18.8 and 22.0 points, respectively, against 14.7 points with placebo. At week 52, total endoscopic remission occurred in 34.4% and 29.5% of patients at the respective doses, versus 4.1% on placebo. The trial enrolled 368 patients aged 12-80 randomized equally to tezspire 210 mg, 420 mg, or placebo, injected subcutaneously every four weeks. Tezspire, developed with Amgen (AMGN), blocks thymic stromal lymphopoietin. AstraZeneca plans to share the data with regulatory authorities. Findings were presented at United European Gastroenterology Week, held October 17-20 in Barcelona. AZN closed Monday at $163.95, down 0.88%, and was recently trading up 2.36% at $167.85.